MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Fortress Biotech Total Assets 2011-2026 | FBIO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Fortress Biotech
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 144 M | 168 M | 294 M | 397 M | 329 M | 226 M | 141 M | 246 M | 171 M | 119 M | 89.3 M | 101 M | 41 M | 23.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 397 M | 23.4 M | 178 M |
Quarterly Total Assets Fortress Biotech
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 181 M | 160 M | 178 M | 144 M | 127 M | 146 M | 165 M | 168 M | 151 M | 181 M | 264 M | 294 M | 324 M | 364 M | 408 M | 397 M | 408 M | 418 M | 391 M | 333 M | 333 M | 333 M | 329 M | 226 M | 226 M | 226 M | 226 M | 141 M | 141 M | 141 M | 141 M | 246 M | 246 M | 246 M | 246 M | 171 M | 171 M | 171 M | 171 M | 119 M | 119 M | 119 M | 119 M | 89.3 M | 89.3 M | 89.3 M | 89.3 M | 101 M | 101 M | 101 M | 101 M | 41 M | 41 M | 41 M | 41 M | 23.4 M | 23.4 M | 23.4 M | 23.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 418 M | 23.4 M | 183 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Altimmune
ALT
|
280 M | $ 3.41 | 2.1 % | $ 300 M |  USA |
 |
Amgen
AMGN
|
90.6 B | $ 350.17 | 0.68 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.63 B | $ 19.57 | 0.36 % | $ 915 M | USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
1.3 B | $ 217.82 | -1.83 % | $ 5 B |  Danmark |
 |
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.4 | 1.82 % | $ 357 M |  Britain |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.64 | 1.15 % | $ 16.6 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | USA |
 |
Benitec Biopharma
BNTC
|
99.6 M | $ 11.0 | 0.18 % | $ 453 M | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
62.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Coherus BioSciences
CHRS
|
258 M | $ 1.58 | 3.62 % | $ 185 M | USA |
 |
Cellectis S.A.
CLLS
|
325 M | $ 3.35 | 0.3 % | $ 116 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
448 M | $ 12.83 | 0.71 % | $ 773 M | USA |
 |
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
8.19 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
64.8 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
126 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
426 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
7.94 M | - | -74.18 % | $ 955 K | USA |
 |
CorMedix
CRMD
|
826 M | $ 6.29 | 0.64 % | $ 453 K | USA |
 |
CytomX Therapeutics
CTMX
|
152 M | $ 4.41 | -1.01 % | $ 608 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
7.47 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
473 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
157 M | $ 2.12 | 1.2 % | $ 198 M | Israel |
 |
Denali Therapeutics
DNLI
|
1.37 B | $ 20.92 | 3.69 % | $ 3.44 B | USA |
 |
Dyadic International
DYAI
|
8.22 M | $ 0.89 | -5.85 % | $ 25.6 M | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
144 M | $ 4.26 | 0.47 % | $ 707 M | Canada |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |